Specificity of Human Antibodies Reactive with Pneumococcal C Polysaccharide

Specificity of human antibodies reactive with pneumococcal C polysaccharide.

Antibodies reactive with C polysaccharide (PS) were found in healthy adults, pneumococcal patients, and vaccinees. These antibodies were not directed to the phosphocholine determinant of the C PS, as they appear to be in mice, since the human antibodies were inhibitable only with C PS. We found another population of phosphocholine-specific antibodies inhibitable only by phosphocholine and relat...

Human C-reactive protein protects mice from Streptococcus pneumoniae infection without binding to pneumococcal C-polysaccharide.

Human C-reactive protein (CRP) protects mice from lethality after infection with virulent Streptococcus pneumoniae type 3. For CRP-mediated protection, the complement system is required; however, the role of complement activation by CRP in the protection is not defined. Based on the in vitro properties of CRP, it has been assumed that protection of mice begins with the binding of CRP to pneumoc...

The chemical composition of pneumococcal C-polysaccharide.

The species-specific C-polysaccharide of the pneumococcus was first described by Tillett, Goebel, and Avery in 1930 (1). The chemical composition was examined by Heidelberger and Kendall (2) and by Goebel et al. (3) ; the latter study showed that the C-polysaccharide contained 4.47% phosphorus, 5.91% nitrogen, 50.6% reducing sugar, 21.8 % hexosamine, and 13.08% acetyl. Detailed information as t...

C-Polysaccharide Bind to Phosphocholine and Pneumococcal A C-Reactive Protein Mutant That Does Not

Estimating the protective concentration of anti-pneumococcal capsular polysaccharide antibodies.

Estimates of minimum protective antibody concentrations for vaccine preventable diseases are of critical importance in assessing whether new vaccines will be as effective as those for which clinical efficacy was shown directly. We describe a method for correlating pneumococcal anticapsular antibody responses of infants immunized with pneumococcal conjugate (PnC) vaccine (Prevenar) with clinical...